Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 15,120 | 27,060 | 25,598 | 23,555 | 25,660 |
| TOTAL | $17,252 | $28,666 | $27,287 | $25,460 | $27,710 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 243 | 306 | 368 | 430 | 490 |
| TOTAL | $243 | $306 | $368 | $430 | $490 |
| Total Assets | $17,495 | $28,972 | $27,655 | $25,890 | $28,200 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,656 | 2,795 | 3,698 | 3,797 | 6,431 |
| Accrued Expenses | 8,204 | 11,586 | 10,856 | 8,836 | 9,182 |
| Other current liabilities | 369 | 359 | N/A | N/A | N/A |
| TOTAL | $35,409 | $25,258 | $14,617 | $12,633 | $15,676 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 85,156 | 96,195 | 95,185 | 84,343 | 72,765 |
| TOTAL | $85,156 | $96,195 | $95,185 | $84,343 | $72,765 |
| Total Liabilities | $120,565 | $121,453 | $109,802 | $96,976 | $88,441 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 63,180 | 62,762 | 62,278 | 62,148 | 61,904 |
| Common Shares | 62 | 62 | 62 | 61 | 61 |
| Retained earnings | -401,572 | -389,542 | -378,304 | -365,869 | -354,372 |
| Other shareholders' equity | 2,223 | 2,223 | 2,223 | 2,223 | 2,223 |
| TOTAL | $-103,070 | $-92,481 | $-82,147 | $-71,086 | $-60,241 |
| Total Liabilities And Equity | $17,495 | $28,972 | $27,655 | $25,890 | $28,200 |